Bob, I was going to tell you how to cut and paste a URL in a private message, but Betty beat me to it,and in public at that. <g> Sure beats the heck out of trying to copy the darn things exactly. I also use this for some search engines.
Something you may have seen posted here before that seems worth thinking about:
Drugs 1998 Apr;55(4):497-508
Antiendotoxin strategies for the prevention and treatment of septic
shock. New approaches and future directions.
Opal SM, Yu RL Jr
Infectious Disease Division, Brown University School of Medicine, Providence, Rhode Island, USA.
Steven_Opal@brown.edu
Therapy for Gram-negative sepsis remains unsatisfactory despite a concerted effort to develop new treatments for this
common, life-threatening syndrome. Current research continues on several fronts to improve the treatment options
available to clinicians in the management of these critically ill patients. Recently, a greater understanding of the complex
molecular basis of endotoxin-mediated pathophysiological effects in humans has generated a number of novel therapeutic
agents for sepsis. Several of these treatment strategies have already entered clinical trials and it is hoped that some of
these therapies will become widely available in the near future. In this review, the current status of the most promising
new antiendotoxin agents is summarised, and the major obstacles to the successful clinical development of these therapies
are described. New antiendotoxin therapies include those which interrupt the synthesis of endotoxin, bind and neutralise
its activity, prevent endotoxin interactions with host effector cells and interfere with endotoxin-mediated signal
transduction pathways. Potential therapeutic strategies involving these agents consist of endotoxin analogues, antibodies,
subunit vaccines, binding columns, recombinant human proteins and small molecule inhibitors of endotoxin synthesis
and intracellular signalling. The pitfalls of previous antiendotoxin clinical investigations and the perils of future clinical
trial designs are discussed in the context of unmet needs and realistic expectations for success. While considerable
progress has been made, effective and new treatments for Gram-negative bacterial sepsis continues to elude us at the
present time. This has been to the detriment of patients, investigators and pharmaceutical companies alike. It will require
focused efforts by basic scientists, continued support by industry and enlightened study designs by clinical investigators
to successfully develop antiendotoxin in therapies for use in septic patients in the future.
THINK ABOUT THIS STATEMENT!
"Several of these treatment strategies have already entered clinical trials and it is hoped that
some of
these therapies will become widely available in the near future."
WONDER IF THERE WILL BE ANY MARKET FOR NEUPREX IF IT WORKS???? <G> |
